Stories

Cultural reportage
and personal essays.

Published intermittently. Always cultural, never prescriptive. Subscribe to the monthly letter to get the next one in your inbox.

All stories.

Analysis · Regulatory + policy

The compounded GLP-1 crackdown: actual timeline, actual losses.

Not a ban — the expiration of a temporary legal exception written into a 1997 statute. Who actually lost: not the drugmakers, but the telehealth layer and the patients paying $199 instead of $1,999.

7 min read · June 15, 2026
Analysis · Regulatory + policy

FDA's peptide reclassification, explained piece by piece.

The 2026 FDA action closed a grey market that was never technically open. Understanding what changed — and what was always illegal — matters for understanding where this goes next.

8 min read · June 12, 2026
Analysis · Clinical data

SELECT: the cardiovascular trial everyone misapplies.

SELECT showed a 20% relative risk reduction in serious cardiac events. But the trial only enrolled patients with established CVD and no diabetes. Here is what the numbers actually say — and for whom.

8 min read · June 10, 2026
Analysis · Clinical data

Discontinuation rates: the data the press release skipped.

The pivotal trials ran 68 weeks. Real-world persistence data shows 23.7% of patients still filling prescriptions at 12 months. The gap between those two numbers is the whole story.

8 min read · June 8, 2026
Analysis · Clinical data analysis

STEP-4: the trial everyone misquotes.

Bulls say it proves the drug keeps working; skeptics say you gain it all back. Both misread the same withdrawal design — and the truth in between is the whole point.

8 min read
Analysis · Clinical data analysis

The body composition data buried in the SURMOUNT trials.

Everyone quotes 20.9%. The body-composition substudy underneath it quietly settles the "muscle loss" panic — and I think almost everyone reads it backwards.

8 min read
Analysis · Clinical data analysis

Retatrutide: the five numbers everyone is ignoring.

Everyone repeats 24%. I think it is the least interesting figure in the Phase 2 data — and the five that matter are what the TRIUMPH readouts will decide.

7 min read
Essay · New

The third way. A cultural letter on the year the body conversation changed.

For a century the equation had two terms: diet and exercise. Then a generation woke up and the sentence had a third. An essay on what that third sentence does to a culture.

9 min read
Cultural · Essay

The "Ozempic personality" — what the science actually says about mood and behavior.

The cultural phenomenon, the honest read on the neuroscience, and what it means for how we talk about pleasure and motivation in the medicated era.

13 min read
Reportage

The first pill. Notes on the year medication moved from the needle to the medicine cabinet.

What it means culturally that the next generation of weight-loss medication is a tablet. How the conversation shifts when the friction of injection disappears.

12 min read
Reportage

The next chapter has a name. Cultural notes on what arrives after the headlines.

Every wave of medication brings its own cultural ripples. A reportage on what is coming, what it means for the conversation, and the questions the data cannot answer.

12 min read

One thoughtful letter, once a month.

The cultural essays, the reading recommendations, the conversation behind the next piece. First Sunday of every month.

Subscribe to the letter